Edoxaban Dose Equivalent to Apixaban 2.5mg Twice Daily
For patients meeting dose-reduction criteria, apixaban 2.5 mg twice daily is equivalent to edoxaban 30 mg once daily. 1, 2
Dosing Framework
The dose equivalence is based on FDA-approved dose-reduction criteria for each agent in atrial fibrillation:
Apixaban Dose Reduction Criteria 3
The standard dose is 5 mg twice daily, reduced to 2.5 mg twice daily when patients meet at least 2 of 3 criteria:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Edoxaban Dose Reduction Criteria 1, 2
The standard dose is 60 mg once daily, reduced to 30 mg once daily when patients meet any 1 of these criteria:
- Creatinine clearance 15-50 mL/min
- Body weight ≤60 kg
- Concomitant use of P-glycoprotein inhibitors (verapamil, quinidine, dronedarone)
Clinical Evidence Supporting Equivalence
Both reduced-dose regimens demonstrated comparable efficacy and safety profiles in their respective pivotal trials 1, 4:
Apixaban 2.5 mg twice daily (ARISTOTLE trial):
- Major bleeding HR: 0.69 (0.60-0.80) vs warfarin
- Stroke/systemic embolism HR: 0.88 (0.74-1.03) vs warfarin
Edoxaban 30 mg once daily (ENGAGE AF-TIMI 48):
- Major bleeding HR: 0.80 (0.71-0.91) vs warfarin
- Stroke/systemic embolism HR: 0.79 (0.66-0.95) vs warfarin
The dose-reduced edoxaban regimen maintained efficacy and safety compared to the 60 mg dose while being safer than warfarin in patients meeting dose-reduction criteria 5.
Critical Dosing Pitfalls
Do not use edoxaban 30 mg in patients with creatinine clearance >95 mL/min - the FDA restricted edoxaban approval to patients with CrCl <95 mL/min due to reduced efficacy at higher renal function 1, 2, 6.
Avoid underdosing: Patients receiving apixaban 2.5 mg twice daily who do NOT meet at least 2 dose-reduction criteria have worse outcomes 7. Similarly, inappropriate dose reduction of edoxaban increases thrombotic risk 8, 9.
Age alone is insufficient for apixaban dose reduction - you need 2 of 3 criteria. However, for edoxaban, age ≥80 years combined with other bleeding risk factors may warrant considering the 30 mg dose even without meeting formal criteria 10.
Practical Conversion
When switching between these agents 3:
- From apixaban 2.5 mg BID to edoxaban: Start edoxaban 30 mg once daily at the time of the next scheduled apixaban dose
- From edoxaban 30 mg daily to apixaban: Start apixaban 2.5 mg twice daily at the time of the next scheduled edoxaban dose
No bridging anticoagulation is required for direct DOAC-to-DOAC switches 2, 6.